乙型肝炎疫苗接种与推测的中枢性脱髓鞘疾病风险——系统综述与荟萃分析
该研究系统检索Medline、Embase、ISI Web of Science和Cochrane Library(建库至2017年5月10日)并纳入13项含对照组的观察性研究,采用随机效应模型合并估计乙型肝炎疫苗接种后多发性硬化及中枢性脱髓鞘疾病风险。调整后风险比分别为1.19(95%CI:0.93-1.52)和1.25(95%CI:0.97-1.62),均未达统计学显著,未发现乙型肝炎疫苗接种与中枢性脱髓鞘疾病相关的证据。
要点
- 纳入13项含对照组的观察性研究,合并多发性硬化及中枢性脱髓鞘疾病风险均未达统计学显著。
- 调整后多发性硬化风险比为1.19(95%CI:0.93-1.52)。
- 调整后中枢性脱髓鞘疾病风险比为1.25(95%CI:0.97-1.62)。
核心结论
- 未发现乙型肝炎疫苗接种与中枢性脱髓鞘疾病相关的证据。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、ISI Web of Science和Cochrane Library(建库至2017年5月10日),并检索灰色文献及滚雪球法,纳入13项含对照组的观察性研究,采用随机效应模型合并粗估计、调整估计或免疫后3个月内风险,遵循PRISMA声明和MOOSE报告规范(研究方案注册于PROSPERO:CRD42015020808)。
主要发现
- 在审查的2804篇参考文献中,最终分析13项含对照组的研究。
- 乙型肝炎免疫后多发性硬化或中枢性脱髓鞘疾病的合并风险估计均未达统计学显著。
- 调整后风险比:多发性硬化为1.19(95%CI:0.93-1.52),中枢性脱髓鞘疾病为1.25(95%CI:0.97-1.62),均未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The anti-hepatitis B immunization campaigns launched in the early 1990s were a major public health breakthrough and targeted various populations (at-risk adults, newborns, adolescents). However, debate is still active about a possible link between this vaccine and central demyelination. This study provides a pooled estimate of this risk based on a comprehensive review and meta-analysis of all available epidemiologic studies. METHODS: A systematic review was conducted in Medline, Embase, ISI Web of Science and the Cochrane Library from database inception to 10 May 2017. Grey literature was searched and snowballing was also undertaken. Only observational studies including a control group were retained. Primary outcome was multiple sclerosis diagnosed by recognized criteria. Study selection was performed by two independent reviewers with disagreements solved through discussion. This meta-analysis based on crude, adjusted estimates, or risks limited to the 3 months following immunization was performed using a generic inverse variance random-effect model. Heterogeneity was investigated; sensitivity and subgroup analyses were performed when necessary. This study followed the PRISMA statement and the MOOSE reporting guideline (Study protocol registered in PROSPERO: CRD42015020808). FINDINGS: Of the 2804 references reviewed, 13 studies with a control group were analysed. None of the pooled risk estimates for either multiple sclerosis or central demyelination following HB immunization reached statistical significance. When considering adjusted risk ratios, the following non-significant figures were obtained: 1.19 (95%CI: 0.93 - 1.52) and 1.25 (95%CI: 0.97 - 1.62), for multiple sclerosis and central demyelination, respectively. CONCLUSIONS: No evidence of an association between hepatitis B vaccination and central demyelination was found.
引用
- Mouchet J, Salvo F, Raschi E, et al. Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. Vaccine. 2018. PMID: 29454521. doi:10.1016/j.vaccine.2018.02.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。